March 25, 2013
/PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceuticals issues, finds that, despite the 2012 launch of Medivation/Astellas Pharma's Xtandi (enzalutamide) for the treatment of docetaxel-pretreated metastatic castrate-resistant prostate cancer (mCRPC), surveyed oncologists report that Johnson & Johnson/Janssen Biotech/Janssen-Cilag's Zytiga continues to dominate the second-line mCRPC setting—although its share dropped marginally from Q3 2012 to Q1 2013. The patient share of Sanofi's Jevtana showed a marked decline over this time period as a result of Xtandi's availability, especially in the third line where Jevtana's patient share in Q1 2013 is half that of its reported share in Q3 2012. The findings are from the
TreatmentTrends ® Prostate Cancer (US) Q1
report, in which 53 urologists and 51 medical oncologists were surveyed about their current and expected treatment practices for prostate cancer.
"In the first-line symptomatic mCRPC setting, docetaxel still dominates treatment according to surveyed oncologists, despite the recent label extension of Zytiga for chemotherapy-naive mCRPC in December 2012," said Decision Resources Group Analyst
, M.Sc. "Nevertheless, surveyed oncologists indicate that Zytiga's patient share for first-line symptomatic mCRPC has almost doubled from Q3 2012 to Q1 2013. Interestingly, both surveyed urologists and oncologists indicate that Xtandi is also prescribed for first-line mCRPC patients, although this off-label use remains minimal due to perceived reimbursement challenges."
Surveyed physicians are most satisfied with Zytiga as a treatment for mCRPC; Dendreon's Provenge and mitoxantrone have the lowest levels of overall satisfaction. Satisfaction scores for the efficacy of therapies used to treat mCRPC are similar in Q1 2013 compared with prior waves of research; however, satisfaction with Xtandi in Q1 2013 is greater than the level of satisfaction with Zytiga in Q1 2012.